Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

8.3%

4 terminated out of 48 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

8%

4 trials in Phase 3/4

Results Transparency

50%

5 of 10 completed with results

Key Signals

5 with results71% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (9)
P 1 (2)
P 2 (7)
P 3 (2)
P 4 (2)

Trial Status

Recruiting17
Unknown11
Completed10
Terminated4
Not Yet Recruiting3
Active Not Recruiting2

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (48)

Showing 20 of 20 trials
NCT06635629Phase 2RecruitingPrimary

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

NCT03604198Phase 2Active Not RecruitingPrimary

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03708900Phase 2RecruitingPrimary

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

NCT06573723Recruiting

Institutional Registry of Rare Diseases

NCT07247162Phase 4Not Yet Recruiting

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

NCT03364803Recruiting

Collecting Information About Treatment Results for Patients With Cushing's Syndrome

NCT07168122Recruiting

Establishment and Clinical Application of Reference Intervals of Salivary Cortisol

NCT04543253RecruitingPrimary

Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)

NCT00669266Recruiting

Adrenal Tumors - Pathogenesis and Therapy

NCT03697109Phase 3CompletedPrimary

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

NCT03621280Phase 3CompletedPrimary

Open-label Treatment in Cushing's Syndrome

NCT06980753Not ApplicableNot Yet RecruitingPrimary

Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders

NCT06962202RecruitingPrimary

Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT

NCT05804669Phase 1RecruitingPrimary

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

NCT03211624Active Not RecruitingPrimary

Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome

NCT05521529RecruitingPrimary

Cushing's Syndrome Before and After Treatment (CORRECT)

NCT06801249Phase 4Recruiting

Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome

NCT05881005Not ApplicableRecruitingPrimary

NAC- NAFLD and Cushing

NCT06326853Not Yet Recruiting

Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models

NCT06229405Recruiting

Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data

Scroll to load more

Research Network

Activity Timeline